Epitome Therapeutics
Develops biotechnology therapeutics programmes, using pre-seed capital to advance its pipeline and expand its team.
Overview
Epitome Therapeutics is an Austrian biotechnology startup developing therapeutic programmes. The provided funding announcement does not disclose its modalities, disease areas or use of AI, so the company is best characterized as a deep-tech drug development venture rather than an AI infrastructure or software business. The company raised €4 million in pre-seed funding, reported as $4 million total raised, to advance its programmes and grow its team. Its target market is the therapeutics and biopharma sector, with differentiation tied to its internal pipeline as further details emerge.
Funding History
Austrian BioTech startup Epitome Therapeutics announces €4 million in funding to advance programmes and grow team
Frequently Asked Questions
- How much funding does AI Funding track for Epitome Therapeutics?
- AI Funding tracks $4M for Epitome Therapeutics across 1 funding round in this database.
- Who are Epitome Therapeutics's investors?
- Epitome Therapeutics's investors include XISTA Science Ventures, Caesar Ventures, Navec Venture Holding GmbH.
- What does Epitome Therapeutics do?
- Epitome Therapeutics is an Austrian biotechnology startup developing therapeutic programmes. The provided funding announcement does not disclose its modalities, disease areas or use of AI, so the company is best characterized as a deep-tech drug development venture rather than an AI infrastructure or software business. The company raised €4 million in pre-seed funding, reported as $4 million total raised, to advance its programmes and grow its team. Its target market is the therapeutics and biopharma sector, with differentiation tied to its internal pipeline as further details emerge.
- Where is Epitome Therapeutics headquartered?
- Epitome Therapeutics is headquartered in San Francisco, CA.
Investors
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.